Meglitinide (BioDeep_00000180708)
human metabolite blood metabolite
代谢物信息卡片
4-{2-[(5-chloro-2-methoxyphenyl)formamido]ethyl}benzoic acid
化学式: C17H16ClNO4 (333.0767806)
中文名称:
谱图信息:
最多检出来源 Mus musculus(blood) 50%
分子结构信息
SMILES: COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)C(=O)O
InChI: InChI=1S/C17H16ClNO4/c1-23-15-7-6-13(18)10-14(15)16(20)19-9-8-11-2-4-12(5-3-11)17(21)22/h2-7,10H,8-9H2,1H3,(H,19,20)(H,21,22)
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent
D007004 - Hypoglycemic Agents
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- PubChem: 41214
- HMDB: HMDB0254413
- ChEMBL: CHEMBL149930
- Wikipedia: Meglitinide
- chemspider: 37613
- CAS: 54870-28-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lili Tong, Sharon Adler. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Postgraduate medicine.
2018 May; 130(4):381-393. doi:
10.1080/00325481.2018.1457397. [PMID: 29667921] - Srikanth Yandrapalli, George Jolly, Adam Horblitt, Abdallah Sanaani, Wilbert S Aronow. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Postgraduate medicine.
2017 Nov; 129(8):811-821. doi:
10.1080/00325481.2017.1358064. [PMID: 28749197] - Bianca Hemmingsen, David Peick Sonne, Maria-Inti Metzendorf, Bernd Richter. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
The Cochrane database of systematic reviews.
2016 Oct; 10(?):CD012151. doi:
10.1002/14651858.cd012151.pub2. [PMID: 27749986] - K Raile, E Schober, K Konrad, A Thon, J Grulich-Henn, T Meissner, J Wölfle, N Scheuing, R W Holl. Treatment of young patients with HNF1A mutations (HNF1A-MODY).
Diabetic medicine : a journal of the British Diabetic Association.
2015 Apr; 32(4):526-30. doi:
10.1111/dme.12662. [PMID: 25483937] - Andreas Holstein, Winfried Beil, Peter Kovacs. CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.
Expert opinion on drug metabolism & toxicology.
2012 Dec; 8(12):1549-63. doi:
10.1517/17425255.2012.722619. [PMID: 23153186] - Jatinder Kaur, Atul Bhardwaj, Zhangjian Huang, Deepak Narang, Ting-Yueh Chen, Frances Plane, Edward E Knaus. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.
Journal of medicinal chemistry.
2012 Sep; 55(17):7883-91. doi:
10.1021/jm300997w. [PMID: 22916833] - Nalinee Poolsup, Naeti Suksomboon, Wanwaree Setwiwattanakul. Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.
ISRN endocrinology.
2012; 2012(?):798146. doi:
10.5402/2012/798146. [PMID: 22619731] - Victor Fang, Lori D Wazny, Colette B Raymond. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
CANNT journal = Journal ACITN.
2012 Jan; 22(1):30-6; quiz 37. doi:
NULL. [PMID: 22558681] - Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim. Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration.
Diabetes & metabolism journal.
2011 Jun; 35(3):290-7. doi:
10.4093/dmj.2011.35.3.290. [PMID: 21785750] - Jeffrey W Chisholm, Allison B Goldfine, Arvinder K Dhalla, Eugene Braunwald, David A Morrow, Ewa Karwatowska-Prokopczuk, Luiz Belardinelli. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
Diabetes care.
2010 Jun; 33(6):1163-8. doi:
10.2337/dc09-2334. [PMID: 20357382] - Robert G Moses. Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update.
Diabetes, metabolic syndrome and obesity : targets and therapy.
2010 May; 3(?):145-54. doi:
10.2147/dmsott.s6621. [PMID: 21437084] - Søren S Lund, Lise Tarnow, Merete Frandsen, Bente B Nielsen, Birgitte V Hansen, Oluf Pedersen, Hans-Henrik Parving, Allan A Vaag. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
BMJ (Clinical research ed.).
2009 Nov; 339(?):b4324. doi:
10.1136/bmj.b4324. [PMID: 19900993] - Ralph A Defronzo, Maryann Banerji, George A Bray, Thomas A Buchanan, Stephen Clement, Robert R Henry, Abbas E Kitabchi, Sunder Mudaliar, Nicolas Musi, Robert Ratner, Peter D Reaven, Dawn Schwenke, Frankie B Stentz, Devjit Tripathy. Actos Now for the prevention of diabetes (ACT NOW) study.
BMC endocrine disorders.
2009 Jul; 9(?):17. doi:
10.1186/1472-6823-9-17. [PMID: 19640291] - Robert Moses. Fixed combination of repaglinide and metformin in the management of type 2 diabetes.
Diabetes, metabolic syndrome and obesity : targets and therapy.
2009 Jun; 2(?):101-9. doi:
10.2147/dmsott.s4436. [PMID: 21437123] - Ole-Petter R Hamnvik, Graham T McMahon. Balancing risk and benefit with oral hypoglycemic drugs.
The Mount Sinai journal of medicine, New York.
2009 Jun; 76(3):234-43. doi:
10.1002/msj.20116. [PMID: 19421967] - Ronald B Goldberg. Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective.
Diabetes, metabolic syndrome and obesity : targets and therapy.
2009 May; 2(?):11-21. doi:
10.2147/dmsott.s3866. [PMID: 21437115] - J N Basile. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.
International journal of clinical practice.
2009 Apr; 63(4):656-66. doi:
10.1111/j.1742-1241.2009.02009.x. [PMID: 19220522] - Hiroki Yokoyama, Teruo Inoue, Koichi Node. Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance.
Diabetes research and clinical practice.
2009 Jan; 83(1):77-82. doi:
10.1016/j.diabres.2008.09.049. [PMID: 19027977] - Mozhgan Dorkhan, Anders Frid, Leif Groop. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?.
Diabetes research and clinical practice.
2008 Dec; 82(3):340-5. doi:
10.1016/j.diabres.2008.09.009. [PMID: 18926586] - Sachin L Badole, Naimesh M Patel, Prasad A Thakurdesai, Subhash L Bodhankar. Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice.
Evidence-based complementary and alternative medicine : eCAM.
2008 Jun; 5(2):159-64. doi:
10.1093/ecam/nem010. [PMID: 18604261] - Mark A Malesker. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Pharmacotherapy.
2008 Feb; 28(2):193-206. doi:
10.1592/phco.28.2.193. [PMID: 18225965] - Enrique Z Fisman, Michael Motro, Alexander Tenenbaum. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
Advances in cardiology.
2008; 45(?):154-170. doi:
10.1159/000115193. [PMID: 18230961] - Els Mehuys, Leen De Bolle, Luc Van Bortel, Lieven Annemans, Inge Van Tongelen, Jean-Paul Remon, Mimi Giri. Medication use and disease management of type 2 diabetes in Belgium.
Pharmacy world & science : PWS.
2008 Jan; 30(1):51-6. doi:
10.1007/s11096-007-9140-0. [PMID: 17588213] - Hiroki Yokoyama, Sakiko Kannno, Ikue Ishimura, Koichi Node. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Metabolism: clinical and experimental.
2007 Nov; 56(11):1458-63. doi:
10.1016/j.metabol.2007.06.010. [PMID: 17950094] - Pankaj Modi. Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus.
Current drug discovery technologies.
2007 Jun; 4(1):39-47. doi:
10.2174/157016307781115476. [PMID: 17630927] - Nicholas Tentolouris, Christina Voulgari, Nicholas Katsilambros. A review of nateglinide in the management of patients with type 2 diabetes.
Vascular health and risk management.
2007; 3(6):797-807. doi:
. [PMID: 18200800] - Kjeld Hermansen, Lene S Mortensen. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Drug safety.
2007; 30(12):1127-42. doi:
10.2165/00002018-200730120-00005. [PMID: 18035865] - André J Scheen. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Clinical pharmacokinetics.
2007; 46(2):93-108. doi:
10.2165/00003088-200746020-00001. [PMID: 17253883] - Wei Zhang, Yi-Jing He, Chun-Ting Han, Zhao-Qian Liu, Qing Li, Lan Fan, Zhi-Rong Tan, Wei-Xia Zhang, Bang-Ning Yu, Dan Wang, Dong-Li Hu, Hong-Hao Zhou. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
British journal of clinical pharmacology.
2006 Nov; 62(5):567-72. doi:
10.1111/j.1365-2125.2006.02686.x. [PMID: 16796707] - S Ristic, C Collober-Maugeais, E Pecher, F Cressier. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Diabetic medicine : a journal of the British Diabetic Association.
2006 Jul; 23(7):757-62. doi:
10.1111/j.1464-5491.2006.01914.x. [PMID: 16842480] - J F Blicklé. Meglitinide analogues: a review of clinical data focused on recent trials.
Diabetes & metabolism.
2006 Apr; 32(2):113-20. doi:
10.1016/s1262-3636(07)70257-4. [PMID: 16735959] - Lauri I Kajosaari, Tiina Jaakkola, Pertti J Neuvonen, Janne T Backman. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
European journal of clinical pharmacology.
2006 Mar; 62(3):217-23. doi:
10.1007/s00228-005-0093-8. [PMID: 16447051] - Mikko Niemi, Janne T Backman, Laura Juntti-Patinen, Mikko Neuvonen, Pertti J Neuvonen. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
British journal of clinical pharmacology.
2005 Aug; 60(2):208-17. doi:
10.1111/j.1365-2125.2005.02385.x. [PMID: 16042675] - André J Scheen. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Drug safety.
2005; 28(7):601-31. doi:
10.2165/00002018-200528070-00004. [PMID: 15963007] - Enrique Z Fisman, Alexander Tenenbaum, Michael Motro, Yehuda Adler. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Herz.
2004 May; 29(3):290-8. doi:
10.1007/s00059-004-2476-5. [PMID: 15167955] - Mikko Niemi, Julian B Leathart, Mikko Neuvonen, Janne T Backman, Ann K Daly, Pertti J Neuvonen. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics.
2003 Oct; 74(4):380-7. doi:
10.1016/s0009-9236(03)00228-5. [PMID: 14534525] - Willy J Malaisse. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Treatments in endocrinology.
2003; 2(6):401-14. doi:
10.2165/00024677-200302060-00004. [PMID: 15981944] - L Best, S Benington. Effects of sulphonylureas on the volume-sensitive anion channel in rat pancreatic beta-cells.
British journal of pharmacology.
1998 Oct; 125(4):874-8. doi:
10.1038/sj.bjp.0702148. [PMID: 9831927] - K Louchami, L Ladrière, H Jijakli, W J Malaisse. Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.
Endocrine.
1998 Jun; 8(3):247-50. doi:
10.1385/endo:8:3:247. [PMID: 9741829] - H Jijakli, S Ulusoy, W J Malaisse. Dynamics of the cationic and secretory responses to A-4166 in perifused pancreatic islets.
Fundamental & clinical pharmacology.
1997; 11(4):300-4. doi:
10.1111/j.1472-8206.1997.tb00842.x. [PMID: 9263759] - L Lins, R Brasseur, W J Malaisse. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
Biochemical pharmacology.
1995 Nov; 50(11):1879-84. doi:
10.1016/s0006-2952(99)80003-3. [PMID: 8615868] - C Schwanstecher, C Dickel, U Panten. Cytosolic nucleotides enhance the tolbutamide sensitivity of the ATP-dependent K+ channel in mouse pancreatic B cells by their combined actions at inhibitory and stimulatory receptors.
Molecular pharmacology.
1992 Mar; 41(3):480-6. doi:
. [PMID: 1545776] - B J Zünkler, G Trube, U Panten. How do sulfonylureas approach their receptor in the B-cell plasma membrane?.
Naunyn-Schmiedeberg's archives of pharmacology.
1989 Sep; 340(3):328-32. doi:
10.1007/bf00168518. [PMID: 2682269] - U Panten, J Burgfeld, F Goerke, M Rennicke, M Schwanstecher, A Wallasch, B J Zünkler, S Lenzen. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
Biochemical pharmacology.
1989 Apr; 38(8):1217-29. doi:
10.1016/0006-2952(89)90327-4. [PMID: 2650685] - B J Zünkler, S Lenzen, K Männer, U Panten, G Trube. Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells.
Naunyn-Schmiedeberg's archives of pharmacology.
1988 Feb; 337(2):225-30. doi:
10.1007/bf00169252. [PMID: 2452991] - G Ribes, E R Trimble, C B Wollheim, J P Blayac, M M Loubatieres-Mariani. Stimulation of pancreatic polypeptide secretion in the dog by hypoglycemic agent HB 699.
The American journal of physiology.
1983 Apr; 244(4):E380-4. doi:
10.1152/ajpendo.1983.244.4.e380. [PMID: 6340523] - J P Blayac, E R Trimble, G Ribes, M M Loubatières-Mariani. [Effect of chronic administration of an acylamino alcoyl derivative of benzoic acid, HB 699, on the pancreatic polypeptide secretion in the dog].
Comptes rendus des seances de la Societe de biologie et de ses filiales.
1982; 176(5):681-4. doi:
NULL. [PMID: 6220772] - G Ribes, E R Trimble, J P Blayac, C B Wollheim, R Puech, M M Loubatières-Mariani. Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog.
Diabetologia.
1981 Apr; 20(4):501-5. doi:
10.1007/bf00253415. [PMID: 6113183]